
Subject	Evaluation Advisory Committee Chair Report
---------	--

Category	For Information
----------	-----------------

Section A: Introduction

- This report provides the Board with an overview of the activities of, and guidance provided by, the Evaluation Advisory Committee (EAC) since the Committee Chair last reported to the Board in June 2023.
- At the in-person EAC meeting on 4-5 October 2023, the EAC provided guidance on: i) progress of the commissioned Gavi 5.1 centralised evaluations including the Zero-Dose Evaluation; ii) the Strategy Operationalisation Evaluation; iii) the Mid-Term Evaluation (MTE) of Gavi's 2021-2025 Strategy; iv) the COVAX Facility Phase 2 Evaluation; v) the current relevance of the centralised evaluation on sustainability/post transition; vi) the operationalisation of the changes to the Gavi Evaluation Policy; and vii) EAC engagement in Gavi 5.1 evaluations.

Overarching issues and guidance

- The EAC continues to consider its remit, voice and practice in supporting a Gavi evaluation portfolio of optimal independence, credibility and utility.
- As discussions about Gavi 6.0 gather pace, the EAC welcomes opportunities to engage with the Secretariat - both at leadership level and through the Monitoring, Evaluation & Learning (MEL) Department – and, with the Gavi Board and its Committees, to foster reflection on how to optimally shape and plan evaluation activities going forward. The EAC sees strengths in current practice underpinning credibility, utility and independence; has begun to discuss areas where further reflection is warranted, including on the EAC's remit, voice and practice; and has begun the process of considering potential future shifts. The MOPAN assessment and a forthcoming Evaluation Function review offer useful inputs into this process.
- There was broad agreement by the EAC on the proposed timeline and process for the Evaluation Function review through 2024. However, the EAC also requested additional visibility showing the alignment with the development of the Gavi 6.0 evaluation workplan – specifically, the EAC is keen to ensure that any changes to remit, voice or practice of the EAC that are agreed following upcoming reviews are in place such that they can be operationalised during the development of the Gavi 6.0 evaluation workplan, and aligned with other aspects of Gavi 6.0 planning.
- On the supplier review, EAC members welcomed the progress to date on this topic and requested that work continue on this topic with EAC focal points and

asked that a meeting be convened prior to the next meeting with partner focal points at the Global Fund to Fight AIDS, Tuberculosis and Malaria and the Global Financing Facility.

Specific guidance on the centralised evaluation portfolio

- Reflecting on the progress of the commissioned Gavi 5.1 centralised evaluations, the EAC advised that in future stages of the multi-phase Zero-Dose evaluation and future evaluations, full consideration should be given, from RFP and resourcing through design and planning stages to analysis and reporting to: i) ensuring sufficient coverage and breadth of country-level perspectives; ii) that full value is gained from prior and ongoing research, evaluation, and learning activities; iii) that evaluation questions, findings, lessons, and recommendations are prioritised and justified to achieve maximum utility; and iv) clarifying how contribution analysis will be done to assess Gavi's contribution to Zero-Dose.
- With respect to the Strategy Operationalisation Evaluation, the EAC noted the ongoing challenge in getting country-level responses to interviews. Members also discussed the need to be clearer about the link between methodology and data and how these is reflected in the findings. The EAC requested: i) that in planning, scoping and sequencing the evaluation workplan for Gavi 6.0, a strategy is developed to minimise the burden on all stakeholders; and ii) more transparency with respect to how data and methodology are linked to findings and recommendations is included in all evaluation reports.
- In relation to the MTE, the EAC discussed overlaps in scope between the MTE and other evaluations, including the Strategy Operationalisation Evaluation, as well as with the Secretariat-led EVOLVE project. The EAC emphasised the importance of further demonstrating in the draft report the added value of the MTE. EAC members also discussed the importance of reaching sub-national voices and requested that the evaluators adequately and transparently weight country perspectives in the draft report.
- For the COVAX Facility Phase 2 Evaluation, the EAC commended the Secretariat for the efforts underway to implement EAC guidance in relation to this joint evaluation. The EAC advised: i) that the methods for the COVAX Phase 2 Evaluation will need to be appropriate for the purpose with a clear rationale for the proposed methodology to be refined during the inception phase; and ii) the evaluation optimally leverages the wealth of evidence, including considering a knowledge gap map analysis in the inception phase.
- With regard to the centralised evaluation on Sustainability/Post-Transition, the Secretariat indicated there had been several key shifts since the evaluation was first discussed prior to the start of Gavi 5.0. EAC members queried the impact of Gavi's funding policies on immunisation programmes and sustainability and noted the proposed timeline and possible information gaps. The EAC agreed: i) a Middle-Income Countries (MICs) evaluation be revisited in 2024; and ii) a

light touch retrospective review could be considered after completion of a desk review to explore gaps/needs, with the EAC engaged in an appropriate manner.

- The EAC Chair report is attached in the form of a presentation as Annex A, the latest EAC decision is attached as Annex B, and the latest EAC meeting guidance is attached as Annex C.

Annexes

Annex A: EAC Chair Report

Annex B: Review of Decisions, 4-5 October 2023

Annex C: EAC Guidance, 4-5 October 2023

EVALUATION ADVISORY COMMITTEE CHAIR REPORT

BOARD MEETING
James Hargreaves
6-7 December 2023, Accra, Ghana

gavi.org

Annex A



Overarching issues and guidance

- Towards Gavi 6.0
- MOPAN, Function Review, Work planning
- Suppliers

Gavi 5.1 Centralised Evaluation Workplan

Evaluation	Supplier	Budget	Year				
			2021	2022	2023	2024	2025
Centralised evaluations of high strategic value to the Board to be commissioned in Gavi 5.1							
Evaluation of Gavi's initial response to COVID-19	EHG	US\$ 594,000	◊	◊			
COVAX Facility and COVAX AMC formative and baseline study	ITAD	US\$ 955,000		◊			
Mid Term Evaluation of Gavi's 2021-2025 Strategy	TBC		◊	◊	◊	◊	
Evaluation of Gavi's contribution to reaching zero-dose children and missed communities	IPSOS		◊	◊	◊	◊	
Evaluation of the operationalisation of Gavi's Strategy through Gavi's policies, programmatic guidance, and use of funding levers	EHG	US\$ 569,000	◊		◊	◊	
Gavi's contribution to sustainability of coverage post-transition: rescoped MICs Approach	TBC						◊
COVAX Facility and COVAX AMC multi-stage evaluation	TBD						
◊	Evaluation commissioning period						
◊	Evaluation implementation and delivery period						
◊	Deliverable that needs to be seen by the Evaluation Advisory Committee						

Progress update – Zero-Dose Evaluation

Evaluation	Guidance	Progress Update
Evaluation of Gavi's contribution to reaching zero-dose children and missed communities	<p>In future stages of the Zero-Dose evaluation and future evaluations, full consideration should be given, from RFP and resourcing through design and planning stages to analysis and reporting, to:</p> <ul style="list-style-type: none"> • Ensuring sufficient coverage and breadth of country-level perspectives through transparent data collection processes and assessment of data strength; • Ensuring full value is gained from prior and ongoing research, evaluation, and learning activities (e.g. Zero-Dose Learning Hub); • Ensuring that Evaluation Questions, findings, lessons, and recommendations are prioritised; and justified to achieve maximum utility; and • Clarifying how contribution analysis will be done to assess Gavi's contribution to Zero-Dose. 	<ul style="list-style-type: none"> • Draft report submitted in November 2023 and reviewed by relevant stakeholders; • Validation workshop with stakeholders to take place on 01 December 2023; • Final report expected 16 January 2024.

Progress update – Mid-Term Evaluation

Evaluation	Guidance	Progress Update
Mid-Term Evaluation of Gavi's 2021-2025 Strategy	<ul style="list-style-type: none"> • EAC requested that evaluators adequately and transparently weight country perspectives in the next draft of the report; • EAC emphasised the importance of demonstrating the added value of the MTE in the next draft of the report. 	<ul style="list-style-type: none"> • Draft report expected in end December 2023 • Validation workshop with stakeholders to take place in Q1 2024; • Technical briefing with the Board planned for March 2024.

Progress update – COVAX Facility Phase 2


Evaluation	Guidance	Progress Update
COVAX Facility Phase 2 Evaluation	<ul style="list-style-type: none"> • The EAC advised that the methods for the COVAX Phase 2 evaluation will need to be appropriate for the purpose with a clear rationale for the proposed methodology to be refined in the inception phase; • The EAC advised COVAX Phase 2 optimally uses existing evidence, including by considering a knowledge gap map analysis in the inception phase. 	<ul style="list-style-type: none"> • Request for Proposal (RfP) published in September 2023 • Post RfP launch webinar held in October 2023 • Estimated contract start date: 15 December 2023

Progress update – Other evaluations

Evaluation	Progress Update
Gavi’s contribution to sustainability of coverage post-transition	Light touch retrospective review to be considered after completion of a desk review to explore gaps/needs, with the EAC engaged in an appropriate manner.

Evaluation close-out update

Annex A



COVID-19

COVAX


COUNTRY PORTAL | COVAX PLATFORM

GLOBAL VACCINE IMPACT CONFERENCE

ETHICS HOTLINE

DONATE

EN | FR

The Vaccine Alliance


OUR ALLIANCE

PROGRAMMES & IMPACT

INVESTING IN GAVI

VACCINESWORK

NEWS & RESOURCES




Home > our impact > Evaluation studies > Evaluation of the operationalisation of Gavi's strategy through policies, programmatic guidance and use of funding levers

< BACK TO EVALUATION STUDIES

Evaluation of the operationalisation of Gavi's strategy through policies, programmatic guidance and use of funding levers

Gavi, the Vaccine Alliance appointed [Euro Health Group \(EHG\)](#) to conduct an evaluation of the operationalisation of Gavi's strategy through policies, programmatic guidance and use of funding levers.



Final evaluation report along with Evaluation Management Response (EMR) and EAC assessment published online on [Gavi's evaluation webpage](#) in November 2023.

Thank you

REVIEW OF DECISIONS

EVALUATION ADVISORY COMMITTEE MEETING

4-5 October 2023, Geneva, Switzerland

Decision 1: Work planning 2: Sustainability/Post-Transition Evaluation ^{Annex B}

The Gavi Alliance Evaluation Advisory Committee:

- **approved** the revised multi-year (2021-2025) centralised evaluation workplan attached as Annex C to Doc 07.

Thank you

EAC GUIDANCE

EVALUATION ADVISORY COMMITTEE MEETING

4-5 October 2023, Geneva, Switzerland

Item 3 – Work planning 1: Evaluation Workplan Update

The Gavi Alliance Evaluation Advisory Committee provided the following formal guidance:

- In future stages of the Zero-Dose evaluation and future evaluations, full consideration should be given, from RFP and resourcing through design and planning stages to analysis and reporting, to:
 - Ensuring sufficient coverage and breadth of country-level perspectives through transparent data collection processes and assessment of data strength;
 - Ensuring full value is gained from prior and ongoing research, evaluation, and learning activities (e.g. Zero-Dose Learning Hub);
 - Ensuring that Evaluation Questions, findings, lessons, and recommendations are prioritised and justified to achieve maximum utility; and
 - Clarifying how contribution analysis will be done to assess Gavi's contribution to Zero-Dose.

Item 4 – Update on the Strategy Operationalisation Evaluation

The Gavi Alliance Evaluation Advisory Committee provided the following formal guidance:

- The EAC requested that in planning, scoping and sequencing the evaluation workplan for Gavi 6.0, a strategy is developed to minimise the burden on all stakeholders; and
- EAC requested more transparency with respect to how data and methodology are linked to findings and recommendations included in all evaluation reports.

Item 5 – Update On the Mid-Term Evaluation

The Gavi Alliance Evaluation Advisory Committee provided the following formal guidance:

- EAC requested that evaluators adequately and transparently weight country perspectives in the next draft of the report; and
- EAC emphasised the importance of demonstrating the added value of the MTE in the next draft of the report.

Item 6 – Update on the COVAX Evaluation – Phase 2 ^{Annex C}

The Gavi Alliance Evaluation Advisory Committee provided the following formal guidance:

- The EAC advised that the methods for the COVAX Phase 2 evaluation will need to be appropriate for the purpose with a clear rationale for the proposed methodology to be refined in the inception phase; and
- The EAC advised COVAX Phase 2 optimally uses existing evidence, including by considering a knowledge gap map analysis in the inception phase.

Item 7 – Work planning 2: Sustainability/Post-Transition Evaluation

The Gavi Alliance Evaluation Advisory Committee provided the following formal guidance:

- The EAC agreed that a MICs evaluation be revisited in 2024; and
- The EAC agreed that evidence on this topic is of strategic importance, and a light touch retrospective review could be considered after completion of a desk review to explore gaps/needs, with the EAC engaged in an appropriate manner.

Item 8 – Evaluation Policy Operationalisation

The Gavi Alliance Evaluation Advisory Committee provided the following formal guidance:

- There was broad agreement by the EAC on the proposed timeline and process for the Evaluation Function review, with a request for additional visibility showing the alignment with the development of the Gavi 6.0 evaluation workplan; The Secretariat should follow up with focal points who will be first points of contact but also keep EAC informed; and
- On supplier review, the EAC requested that work continue on this topic with EAC focal points and asked that a meeting be convened prior to the next meeting with partner focal points at the Global Fund to Fight AIDS, Tuberculosis and Malaria and the Global Financing Facility.

Thank you